113 related articles for article (PubMed ID: 11328779)
1. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
Ho PL; Yam WC; Que TL; Tsang DN; Seto WH; Ng TK; Ng WS
J Antimicrob Chemother; 2001 May; 47(5):655-8. PubMed ID: 11328779
[TBL] [Abstract][Full Text] [Related]
2. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
3. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
5. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
6. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.
Piddock LJ; Johnson MM; Simjee S; Pumbwe L
Antimicrob Agents Chemother; 2002 Mar; 46(3):808-12. PubMed ID: 11850265
[TBL] [Abstract][Full Text] [Related]
7. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
Stewart BA; Johnson AP; Woodford N
J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
Bast DJ; Low DE; Duncan CL; Kilburn L; Mandell LA; Davidson RJ; de Azavedo JC
Antimicrob Agents Chemother; 2000 Nov; 44(11):3049-54. PubMed ID: 11036021
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
11. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
12. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
Heaton VJ; Goldsmith CE; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 1999 Dec; 43(12):2998-3000. PubMed ID: 10582896
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Jones ME; Sahm DF; Martin N; Scheuring S; Heisig P; Thornsberry C; Köhrer K; Schmitz FJ
Antimicrob Agents Chemother; 2000 Feb; 44(2):462-6. PubMed ID: 10639387
[TBL] [Abstract][Full Text] [Related]
14. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
15. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.
Ho PL; Yung RW; Tsang DN; Que TL; Ho M; Seto WH; Ng TK; Yam WC; Ng WW
J Antimicrob Chemother; 2001 Nov; 48(5):659-65. PubMed ID: 11679555
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones.
Kawamura-Sato K; Hasegawa T; Torii K; Ito H; Ohta M
Curr Microbiol; 2005 Jul; 51(1):27-30. PubMed ID: 15942701
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
19. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
Avrain L; Garvey M; Mesaros N; Glupczynski Y; Mingeot-Leclercq MP; Piddock LJ; Tulkens PM; Vanhoof R; Van Bambeke F
J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
[TBL] [Abstract][Full Text] [Related]
20. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Coyle EA; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
